Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

KKIORA PHARMACEUTICALS INC

EconomyAI buildoutMarket MapFundsWatchlist
Log in
K

KIORA PHARMACEUTICALS INC

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
    Sep 8, 2026Kiora Pharmaceuticals, Inc. (KPRX) News Releases
  • Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
    Aug 19, 2026Kiora Pharmaceuticals, Inc. (KPRX) News Releases
  • Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
    Aug 7, 2026Kiora Pharmaceuticals, Inc. (KPRX) News Releases
  • Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
    Jul 2, 2026Kiora Pharmaceuticals, Inc. (KPRX) News Releases
  • Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
    Jun 18, 2026Kiora Pharmaceuticals, Inc. (KPRX) News Releases
  • Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
    May 8, 2026Kiora Pharmaceuticals, Inc. (KPRX) News Releases
  • Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
    Apr 14, 2026Kiora Pharmaceuticals, Inc. (KPRX) News Releases
  • Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors
    Apr 7, 2026Kiora Pharmaceuticals, Inc. (KPRX) News Releases
  • Kiora Pharmaceuticals Announces Management Team Changes
    Apr 2, 2026Kiora Pharmaceuticals, Inc. (KPRX) News Releases
  • Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials
    Mar 25, 2026Kiora Pharmaceuticals, Inc. (KPRX) News Releases
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions
$2.71Close ยท Sep 22, 2026